The Zhitong Finance App learned that according to data published in the “Nature Metabolism” (Nature Metabolism) journal, the weight loss drug being studied by AMGN.US (AMGN.US) showed positive pre-clinical results, which indicates that the pharmaceutical company is about to compete fiercely with Eli Lilly and Novo Nordisk in the field of obesity treatment.
The data showed that in two preclinical models, maridebart cafraglutide (AMG 133 or mariTide) effectively reduced body weight and improved metabolic indicators. AMG 133 had acceptable safety and tolerability as well as dose-dependent weight loss in a phase 1 clinical study.
The study also showed that weight loss can continue for 150 days after the last dose. The drug has a combined effect of an anti-gipr monoclonal antibody (mAb) and a GLP-1 receptor agonist, showing a more obvious weight loss effect in preclinical obesity models than using any drug alone.
The results of Amgen's phase II trial are expected to be announced later this year. The continued effectiveness of AMG 133 will be a key differentiator compared to current leaders in obesity treatment — Novo Nordisk's Wegovy and Eli Lilly's Zepbound.